Background: Poorly differentiated thyroid cancer (PDTC) is now classified as a separate thyroid tumor entity. It has male predominance and poor prognosis compared to differentiated TC.
Case: We report a case of a patient with PDTC who was previously deemed inoperable. A trial of neoadjuvant lenvatinib therapy was given to the patient after that the tumor become operable and the surgery went successfully.
Conclusions: Lenvatinib is a feasible option in patients with inoperable TC and can stabilize the lesion size or even reduce it, leading to a more favorable surgical outcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842697 | PMC |
| http://dx.doi.org/10.1002/cnr2.1466 | DOI Listing |
Publication Analysis
Top Keywords
neoadjuvant lenvatinib
8
thyroid cancer
8
lenvatinib inoperable
4
inoperable thyroid
4
cancer case
4
case report
4
report literature
4
literature review
4
review background
4
background differentiated
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!